The new ILAP TDP: de-risking development through early insights and improved coordination

26th March 2026

Summary: The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced a revised Target Development Profile (TDP) within the Innovative Licensing and Access Pathway (ILAP), designed to support developers with clearer, earlier regulatory and system-wide insights. The TDP aims to reduce uncertainty by aligning stakeholders, improving coordination across the development lifecycle, and helping companies make better informed decisions sooner. By offering structured guidance and a more predictable framework, the updated ILAP process seeks to accelerate the delivery of innovative medicines to patients while reducing development risk.

Link: https://medregs.blog.gov.uk/2026/03/26/the-new-ilap-tdp-de-risking-development-by-bringing-early-insights-predictability-and-improved-coordination-for-developers/

Back to Recent News